Beyond HER2: Targeting the ErbB receptor family in breast cancer.

Autor: Drago JZ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weil Cornell Medicine, New York, NY, USA. Electronic address: dragoj@mskcc.org., Ferraro E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Abuhadra N; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weil Cornell Medicine, New York, NY, USA., Modi S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weil Cornell Medicine, New York, NY, USA.
Jazyk: angličtina
Zdroj: Cancer treatment reviews [Cancer Treat Rev] 2022 Sep; Vol. 109, pp. 102436. Date of Electronic Publication: 2022 Jul 15.
DOI: 10.1016/j.ctrv.2022.102436
Abstrakt: Targeting the HER2 oncogene represents one of the greatest advances in the treatment of breast cancer. HER2 is one member of the ERBB-receptor family, which includes EGFR (HER1), HER3 and HER4. In the presence or absence of underling genomic aberrations such as mutations or amplification events, intricate interactions between these proteins on the cell membrane lead to downstream signaling that encourages cancer growth and proliferation. In this Review, we contextualize efforts to pharmacologically target the ErbB receptor family beyond HER2, with a focus on EGFR and HER3. Preclinical and clinical efforts are synthesized. We discuss successes and failures of this approach to date, summarize lessons learned, and propose a way forward that invokes new therapeutic modalities such as antibody drug conjugates (ADCs), combination strategies, and patient selection through rational biomarkers.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: